Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
5,796 USD | +0,29% | +5,01% | +25,03% |
Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 53 | 01/11/06 |
Director of Finance/CFO | 40 | 01/05/13 | |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/22 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/21 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/11 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01/10/14 |
Human Resources Officer | 62 | 01/01/07 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 73 | 15/07/21 | |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Yaky Yanay
CEO | Chief Executive Officer | 53 | 01/11/06 |
Director/Board Member | 54 | 06/01/21 | |
Director/Board Member | 62 | 01/06/21 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 5 388 792 | 4 204 128 ( 78,02 %) | 0 | 78,02 % |
Coordinate società
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
+25,03% | 31,24 Mln | |
+16,71% | 44,48 Mrd | |
+42,66% | 40,57 Mrd | |
-7,92% | 38,82 Mrd | |
+33,09% | 32,22 Mrd | |
-7,10% | 27,84 Mrd | |
+14,46% | 26,79 Mrd | |
+46,73% | 14,31 Mrd | |
+34,07% | 12,7 Mrd | |
-7,61% | 11,23 Mrd |
- Borsa valori
- Azioni
- Azione PLUR
- Società Pluri Inc.